Despite the relative appeal of CD33 as an AML tumor-associated antigen (TAA), therapeutics targeting CD33 have substantial clinical toxicity, presumably caused at least in part by expression on healthy myeloid cells (9–11). This evidence concerns the gene CD33 and neoplasm.